DBS has issued a research report initiating coverage on EDGE MEDICAL-B (02675) with a "Buy" rating and a target price of HK$68.1. The report forecasts an average annual compound profit growth rate of 187% for the period from 2026 to 2028. Additionally, revenue is projected to grow at a compound annual rate of 49% from 2026 to 2030, reaching RMB 4.3 billion. The bank anticipates that EDGE MEDICAL-B will achieve breakeven by 2026, driven by the key advantages of its core product, the MP1000. DBS identifies overseas markets as the primary growth driver for the company, which has currently obtained registration approvals in 55 countries and regions. However, it is noted that global tensions could potentially slow down the company's market penetration efforts.